Roche Pares Back To Specialty Care: U.S. Sales Force Will Be Cut By 24%
Executive Summary
Roche will concentrate on specialty care products in the U.S. as part of the restructuring of its global pharmaceutical division.
You may also be interested in...
Roche Specialty Market Focus Provides Refuge In “Unstable Environment”
Roche's return to prominence in the primary care market will wait until at least 2006, the company indicated during a July 24 analyst meeting in Zurich
Roche Specialty Market Focus Provides Refuge In “Unstable Environment”
Roche's return to prominence in the primary care market will wait until at least 2006, the company indicated during a July 24 analyst meeting in Zurich
Roche Sees Pegasys Approval Delay Until 2002, But With Broader Indication
Roche's "current expectation" for the pegylated interferon product Pegasys is that it will be approved in the first half of 2002, with an indication covering both monotherapy and combination use.